Open access
Open access
Powered by Google Translator Translator

EBM & Clinical Trials

Opinion: Using Controlled Trials to Resolve Key Unknowns About Policy During the COVID-19 Pandemic

29 May, 2020 | 03:27h | UTC

Using Controlled Trials to Resolve Key Unknowns About Policy During the COVID-19 Pandemic – JAMA

 


Conducting Clinical Research During the COVID-19 Pandemic: Protecting Scientific Integrity

29 May, 2020 | 03:26h | UTC

Conducting Clinical Research During the COVID-19 Pandemic: Protecting Scientific Integrity – JAMA

 


Review of Trials Currently Testing Treatment and Prevention of COVID-19

28 May, 2020 | 09:48h | UTC

Review of trials currently testing treatment and prevention of COVID-19 – Clinical Microbiology and Infection

 


WHO: Revealing the Toll of COVID-19 – A Technical Package for Rapid Mortality Surveillance and Epidemic Response

27 May, 2020 | 02:48h | UTC

Revealing the toll of COVID-19: A technical package for rapid mortality surveillance and epidemic response – World Health Organization

 

Related Commentary on Twitter

 


Perspective: The Totality of the Evidence, by Dr. John Ioannidis

27 May, 2020 | 02:29h | UTC

The Totality of the Evidence – Boston Review

See other interesting perspectives from the Boston Review: Models v. Evidence AND Good Science Is Good Science

“Given what we know now, it is reasonable to consider alternatives to population-wide lockdown, even as we focus on protecting those most at risk and support health care systems to care for patients who are sick.”

 


Preprinting a Pandemic: The Role of Preprints in the COVID-19 Pandemic

27 May, 2020 | 02:25h | UTC

Preprinting a pandemic: the role of preprints in the COVID-19 pandemic – bioRxiv

 


Reasons to Worry Less About the Explosion of Preprints

27 May, 2020 | 02:24h | UTC

Reasons to Worry Less About the Explosion of Preprints – Absolutely Maybe Blog

 


Perspective: “Here’s What Needs to Happen Before We Can All Get Vaccinated for COVID-19”

26 May, 2020 | 09:45h | UTC

Here’s what needs to happen before we can all get vaccinated for COVID-19 – CBC

 


Impact of COVID-19 on Oncology Clinical Trials

26 May, 2020 | 09:40h | UTC

Impact of COVID-19 on oncology clinical trials – Nature Reviews Drug Discovery

Commentary: More Than 200 International Cancer Trials Suspended Due to COVID-19 – Medscape (free registration required)

 


WHO Pauses Hydroxychloroquine Arm Of COVID-19 Clinical Trial Due to Safety Concerns

26 May, 2020 | 09:35h | UTC

WHO Pauses Hydroxychloroquine Arm Of COVID-19 Clinical Trial – After Lancet Study Finds Higher Mortality Rate Among Patients Getting The Drug – Health Policy Watch

See also: WHO halts hydroxychloroquine trial for coronavirus amid safety fears – The Guardian AND WHO Halts Hydroxychloroquine Trial Over Safety Concerns – NPR

 


Editorial – SARS-CoV2 Vaccines: Slow is Fast

25 May, 2020 | 01:54h | UTC

SARS-CoV2 vaccines: Slow is fast – Science

 


Open Access: How COVID-19 will Change the Way Research Findings are Shared

22 May, 2020 | 04:48h | UTC

Open access: how COVID-19 will change the way research findings are shared – Wellcome

Related: Plan S: Making Full and Immediate Open Access a Reality AND UC Terminates Subscriptions with World’s Largest Scientific Publisher in Push for Open Access (several resources on the subject) AND PLOS and the University of California announce open access publishing agreement – PLOS Blogs AND The war to free science – Vox (free) AND WHO Joins Coalition for Free Digital Access to Health Research

 


A Critical Look at A Preprint Inferring the Covid-19 Infection Fatality Rate

21 May, 2020 | 09:21h | UTC

A Critical Look at A Preprint Inferring the Covid-19 Infection Fatality Rate – by Hilda Bastian

Original Preprint: The infection fatality rate of COVID-19 inferred from seroprevalence data – medRxiv

 


Open-access Science Funders Announce Price Transparency Rules for Publishers

19 May, 2020 | 04:12h | UTC

Open-access science funders announce price transparency rules for publishers – Science

Original Guidance: Plan S Price Transparency Frameworks: guidance & requirements – Plan S

News Release: cOAlition S announces price transparency requirements – Plan S

Related: Plan S: Making Full and Immediate Open Access a Reality AND UC Terminates Subscriptions with World’s Largest Scientific Publisher in Push for Open Access (several resources on the subject) AND PLOS and the University of California announce open access publishing agreement – PLOS Blogs AND The war to free science – Vox (free) AND WHO Joins Coalition for Free Digital Access to Health Research

 


Wrong but Useful — What Covid-19 Epidemiologic Models Can and Cannot Tell Us

18 May, 2020 | 01:48h | UTC

Wrong but Useful — What Covid-19 Epidemiologic Models Can and Cannot Tell Us – New England Journal of Medicine

Related: Modelling the pandemic – The BMJ AND Predictive Mathematical Models of the COVID-19 Pandemic (several commentaries on the subject)

 


Podcast: Finding Reliable Information about Covid-19

15 May, 2020 | 03:36h | UTC

Audio Interview: Finding Reliable Information about Covid-19 – New England Journal of Medicine

 


Editorial: Waste in Covid-19 Research

13 May, 2020 | 02:17h | UTC

Waste in covid-19 research – The BMJ

Related Landmark Paper from the Author: Avoidable waste in the production and reporting of research evidence – The Lancet (free registration required)

 

Related Commentary on Twitter

 


Study Commentary – Virus Wars: Return of Lopinavir/Ritonavir (Along with Ribavirin and Interferon)

13 May, 2020 | 02:12h | UTC

Virus Wars: Return of Lopinavir/Ritonavir (along with ribavirin and interferon) – PulmCrit

Original Article: Triple Therapy Antiviral Combination Seems Promising for COVID-19 in Open-label, Randomized, Phase 2 Trial (study and commentaries)

 


Richard Lehman’s Covid-19 Reviews—11 May 2020

12 May, 2020 | 03:22h | UTC

Richard Lehman’s Covid-19 Reviews, 11 May 2020 – The BMJ Opinion

In this weekly round-up, Richard Lehman looks at a personal selection of articles of relevance to clinicians dealing with covid-19

 


Frequency of Medical Reversal Among Published Randomized Controlled Trials Assessing Cardiopulmonary Resuscitation

12 May, 2020 | 03:08h | UTC

Frequency of Medical Reversal Among Published Randomized Controlled Trials Assessing Cardiopulmonary Resuscitation (CPR) – Mayo Clinic Proceedings

Related: Medical Reversals in Family Practice: A Review – Current Therapeutic Research AND Meta-Research: A Comprehensive Review of Randomized Trials Leading to “Medical Reversals” in Three Medical Journals

 


COVID-19 Research in Brief: 2 May to 8 May, 2020

11 May, 2020 | 00:24h | UTC

COVID-19 Research in Brief: 2 May to 8 May, 2020 – Nature Medicine

 


Perspective: When Should Clinicians Act on Non–Statistically Significant Results From Clinical Trials?

11 May, 2020 | 00:23h | UTC

When Should Clinicians Act on Non–Statistically Significant Results From Clinical Trials? – JAMA (via @AndersPerner)

Author Interview: When Should Physicians Act on Non–Statistically Significant Results From Clinical Trials?

“The burden of proof required to do “more” should probably be higher than to do “less,” particularly if doing “more” is likely to increase overall health care costs.”

 


Opinion – Can We Discuss Flatten-the-Curve in COVID19? My Eight Assertions

6 May, 2020 | 03:54h | UTC

Can We Discuss Flatten-the-Curve in COVID19? My Eight Assertions – Dr. John M

 


Opinion – Mutant Coronavirus Story Upsets Scientists About Preprint Journalism

6 May, 2020 | 03:51h | UTC

Mutant coronavirus story upsets scientists about preprint journalism – HealthNewsReview

Original Story: Scientists say a now-dominant strain of the coronavirus appears to be more contagious than original – Los Angeles Times

Original Preprint Study: Spike mutation pipeline reveals the emergence of a more transmissible form of SARS-CoV-2 – bioRxiv

 


Perspective: Treatments Can Harm

6 May, 2020 | 03:38h | UTC

Treatments can harm – Evidently Cochrane

Related: Treatments can harm – Students 4 Best Evidence (commentary and EBM resource) AND Patients’ Expectations of the Benefits and Harms of Treatments, Screening, and Tests: A Systematic Review – JAMA Internal Medicine AND If Patients Only Knew How Often Treatments Could Harm Them – The New York Times